Corona Remedies
1,701.20
+16.60(+0.99%)
Market Cap₹10,404.55 Cr
PE Ratio55.58
IndustryHealthcare
Company Performance:
1D+0.99%
1M+4.30%
6M+18.27%
1Y+18.27%
5Y+18.27%
View Company Insightsright
More news about Corona Remedies
07Apr 26
Corona Remedies Reports 87% OCF to EBITDA Ratio, Eyes Further Acquisitions
Corona Remedies has announced an operating cash flow to EBITDA ratio of around 87%, demonstrating strong cash generation capabilities. The company stated that this robust financial position provides adequate room for pursuing further acquisitions as part of its growth strategy, indicating strong operational efficiency and financial flexibility for strategic expansion.
 no imag found
07Apr 26
Corona Remedies Reports ₹112 Crore Cash Reserves, Sets 20-25% Growth Target for Wpladone
Corona Remedies announced cash reserves of ₹112 crore as of December 31 and set a growth target of 20-25% CAGR for its Wpladone product over the next three years. The strong cash position provides financial stability to support the company's ambitious growth strategy.
 no imag found
31Mar 26
CORONA Remedies Limited Acquires Wokadine® Brand from Dr. Reddy's Laboratories in Strategic Deal
CORONA Remedies Limited announced the strategic acquisition of Wokadine® from Dr. Reddy's Laboratories, effective March 30, 2026. This fifth acquisition enables entry into the INR 648 Cr Povidone Iodine market, where Wokadine® holds the #2 position. The brand comprises 14 SKUs and will be integrated into CORONA's existing portfolio to enhance market penetration across multiple medical specialties.
 no imag found
Corona Remedies
1,701.20
+16.60
(+0.99%)
1 Year Returns:+18.27%
Industry Peers
Sun Pharmaceutical
1,840.60
(-0.22%)
Divis Laboratories
6,756.50
(-1.89%)
Torrent Pharmaceuticals
4,572.60
(+1.93%)
Cipla
1,413.90
(+1.05%)
Dr Reddys Laboratories
1,331.40
(+1.85%)
Zydus Life Science
1,072.95
(+3.27%)
Lupin
2,287.20
(+0.24%)
Mankind Pharma
2,457.50
(-0.88%)
Aurobindo Pharma
1,454.60
(-0.61%)
Laurus Labs
1,356.30
(+0.95%)